Poor
Not Aligned
Patient Risk:
Low
Summary
Five extracted claims about patent exclusivity and regulatory exclusivities are not present in the FDA-approved labeling; all claims are not supported by label content.
Category Scores
Accurate Statements
Unsupported Statements
Patent expiration drives loss of exclusivity for Enhertu; generic/biosimilar manufacturers can't launch until key patents expire (or are successfully designed around or invalidated).
Not present in FDA-approved labeling.
Regulatory exclusivities can apply even if patents expire; these exclusivities vary by country.
Not present in FDA-approved labeling.
Market exclusivity is tied to specific indications; exclusivity can differ by cancer type or line of therapy, because patents may cover formulation/dosage, manufacturing process, or specific indications or combinations.
Not present in FDA-approved labeling.
For antibody-drug conjugates like Enhertu, the true loss of exclusivity often depends on a patent landscape that can include multiple patent families (compound, process, formulation, linker/payload, method-of-use, etc.).
Not present in FDA-approved labeling.
Therefore the earliest key patent expiration date may not equal the last barrier for competitors.
Not present in FDA-approved labeling.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Claims address patent/regulatory exclusivity topics and do not present patient safety risks or on-label clinical guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Claims pertain to patent exclusivity and regulatory exclusivities rather than label content.
Suggested Improvement
Limit analysis to on-label indications, dosing, safety, and other label-approved content; clearly separate patent/regulatory exclusivity discussions as external to labeling.